ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Dow licenses drug patents ...

June 14, 2004 | APPEARED IN VOLUME 82, ISSUE 24

Dow Chemical has licensed patents from Epicyte Pharmaceutical related to the expression of antibodies in plants. The deal replaces an earlier development agreement between the two firms that ended when Epicyte was acquired last month. Dow's Dowpharma and Dow AgroSciences units are both pursuing the production of therapeutic proteins in plants. Earlier this year, Dowpharma formed a collaboration with Nobex for plant-based production of a peptide being developed as an appetite suppressant. Separately, Dow is moving its biopharmaceutical process development capabilities from Stony Brook, N.Y., to San Diego, Calif., home of its corporate biotechnology R&D center.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment